Hjem › Endometriekreft › Missouri › St. Louis
Kliniske studier for Endometriekreft i St. Louis, MO
29 studier for Endometriekreft søker deltakere på steder i og rundt St. Louis (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
RekruttererFase 3
- Washington University School of Medicine, St Louis
- Cancer Care Center of O'Fallon, O'Fallon · 16 mi unna
- HSHS Saint Elizabeth's Hospital, O'Fallon · 16 mi unna
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
RekruttererFase 2
- Washington University School of Medicine, St Louis
- Mercy Hospital South, St Louis
- Siteman Cancer Center-South County, St Louis
- og 6 flere
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
RekruttererFase 1
- Washington University Medicine, St Louis
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
RekruttererFase 2
- Washington University, School of Medicine, St Louis
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
RekruttererFase 2
- Washington University School of Medicine, St Louis
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
RekruttererFase 1
- Research Site, St Louis
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
RekruttererFase 2
- Washington University School of Medicine, St Louis
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
RekruttererFase 1
- Washington University, St Louis
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
RekruttererFase 1/2
- Washington Univ. School of Medicine, St Louis
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RekruttererFase 1/2
- Research Site, St Louis
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
RekruttererFase 3
- Washington University School of Medicine, St Louis
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
RekruttererFase 3
- Research Site, St Louis
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
RekruttererFase 1
- Washington University School of Medicine - Siteman Cancer Center, St Louis
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
RekruttererFase 1/2
- Washington University School of Medicine, St Louis
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
RekruttererFase 1
- Washington University, Siteman Cancer Center, St Louis
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
RekruttererFase 1
- Normunity Investigational Site, St Louis
FOG-001 in Locally Advanced or Metastatic Solid Tumors
RekruttererFase 1/2
- Washington University School of Medicine, St Louis
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RekruttererFase 1/2
- Washington University, St Louis
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
RekruttererFase 1
- Investigative Site #110, St Louis
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
RekruttererFase 2
- 521, St Louis
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
RekruttererFase 1/2
- Washington University, St Louis
Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
RekruttererObservasjonsstudie
- Mercy Hospital - South, St Louis
- Mercy Hospital -STL, St Louis
A Study of LY4175408 in Participants With Advanced Cancer
RekruttererFase 1
- Washington University, St Louis
Uterine Preservation Via Lifestyle Transformation
RekruttererFase 2
- Washington University School of Medicine, St Louis
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
RekruttererFase 1
- Washington University Medical Campus, St Louis
Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
RekruttererFase 1
- Washington University School of Medicine, St Louis
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekruttererObservasjonsstudie
- Massive Bio SYNERGY-AI site, St Louis
Mindfulness in Endometrial and Cervical Cancer
RekruttererFrivillige helsepersonell ønskes velkommen
- Saint Louis University, St Louis
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
RekruttererFase 2/3
- Washington University School of Medicine, St Louis
Endometriekreft-studier i andre byer
- Houston, TX68 studier
- New York City, NY52 studier
- Boston, MA50 studier
- Arlington, VA39 studier
- Nashville, TN38 studier
- Los Angeles, CA34 studier
- Philadelphia, PA28 studier
- San Antonio, TX27 studier
- Columbus, OH25 studier
- Oklahoma City, OK25 studier
- Chicago, IL25 studier
- Queens, NY25 studier
Andre studier i St. Louis
- Ikke-småcellet lungekreft73 studier
- Brystkreft64 studier
- Metastatisk kreft54 studier
- Kolorektal kreft50 studier
- Kreft (alle typer)46 studier
- Prostatakreft46 studier
- Lungekreft39 studier
- Eggstokkreft38 studier
- Pankreaskreft33 studier
- Plateepitelcancer i hode og hals28 studier
- Hjertesvikt26 studier
- Fedme25 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.